Nashville, July 18, 2011 –VenX, LLC, a medical device company dedicated to revolutionizing the treatment of spider and reticular veins, is pleased to announce that the company has received 510(k) clearance from the FDA for its VenX Revolution™device.
“We are very excited about receiving FDA clearance for the VenX Revolution™ and being one step closer to bringing this revolutionary reticular and spider vein treatment to market. We are currently completing our final clinical trials and working towards launching the product,” said Navroze Mehta, President and CEO of VenX.
Sclerotherapy is currently the most commonly used spider vein treatment available, but it can result in side effects such as staining, matting and potential for ulceration, along with other systemic complications. “The VenX Revolution™ device was developed to be one more tool in the tool box, so to speak, to expand the options to treat common vein disorders,” said Dr. Andrew Jones, vein specialist at the Inovia Vein Specialty Center and co-inventor of the technology.
Citing the common limitations of the current treatments available to treat spider and reticular veins, the founders of VenX set out to develop novel systems to treat these common vein disorders. Dr. Edward Boyle and Dr. Andrew Jones, experienced vein doctors at Inovia Vein Specialty Center in Bend, Oregon, teamed up with clinical experts and design specialists from around the world and developed a device that they termed the VenX Revolution™ to treat and eliminate spider and reticular veins in a transdermal fashion. For more information on the Nashville, Tennessee-based VenX or the VenX Revolution™, please visitwww.venxmedical.com.